Octopamine and phenylethylamine inhibit prolactin secretion both in vivo and in vitro.
Trace amines are a group of biogenic amines that are present in neural tissue in concentrations ranging from 0.1 to 100 ng/g. In the present work, we examined the action of two trace amines, octopamine and phenylethylamine, which are found in the hypothalamus, on pituitary hormone secretion in different experimental situations in vivo and in dispersed anterior pituitary cells. Both octopamine and phenylethylamine decreased high prolactin levels due to swimming or immobilization stress without affecting other adenohypophysial hormones. With regard to the hypoprolactinemic potencies in the immobilization stress model, it was observed that p-tyramine, another trace amine, was as potent as octopamine. Phenylethylamine was the least effective. To evaluate the site of action of the effect described, the three trace amines were tested in dispersed anterior pituitary cell cultures in vitro. Tyramine and octopamine reduced prolactin secretion in a concentration-dependent manner, at concentrations of 10(-8) to 10(-5) M, whereas the hypoprolactinemic effect observed for phenylethylamine was very weak. In pharmacologic experiments, neither octopamine nor phenylethylamine reduced prolactin release when dopaminergic receptors were blocked. This could mean that their hypoprolactinemic action was mediated through the release of dopamine, or it could be a direct action at a dopaminergic receptor. This is the first description of a specific endocrine action both in vivo and in vitro for octopamine and phenylethylamine. Further studies are needed to ascertain the physiologic or pathologic implication of these findings.
Becú-Villalobos
D
D
Laboratorio de Neuroendocrinología, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina.
Thyssen
S M
SM
Rey
E B
EB
Lux-Lantos
V
V
Libertun
C
C
D000704:Analysis of Variance; D000818:Animals; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D006966:Hyperprolactinemia / Q000188:drug therapy; D007103:Immobilization; D066298:In Vitro Techniques; D008297:Male; D009655:Octopamine / Q000494:pharmacology*; D010627:Phenethylamines / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D013550:Swimming; D014439:Tyramine / Q000494:pharmacology
D010627:Phenethylamines; D009655:Octopamine; D011388:Prolactin; D006220:Haloperidol; D004298:Dopamine; D014439:Tyramine